ArticleGenes & genomics2025
A prognostic model for basal-like breast cancer based on beta-alanine metabolism genes: EHHADH as a potential biomarker and target for drug screening.
Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high heterogeneity of basal-like breast cancer (BLBC) impedes early diagnosis and accurate prognosis. Beta-alanine, a non-essential amino acid involved in various metabolic pathways, accumulates in BLBC cells and may exacerbate tumor progression.
objectiveThis study aimed to develop a prognostic model based on beta-alanine metabolism genes and investigate the clinical significance and therapeutic potential of EHHADH in BLBC.
methodsWe applied Least Absolute Shrinkage and Selection Operator regression to 22 beta-alanine metabolism genes to construct a prognostic model using transcriptomic data. Subsequent analyses included overall survival, mutation landscape, functional enrichment, drug sensitivity, and in vitro validation of EHHADH function. Structure-based virtual screening was conducted to identify potential EHHADH inhibitors.
resultsA beta-alanine metabolism-related prognostic signature was successfully developed. EHHADH was identified as a risk gene negatively associated with survival. High EHHADH expression correlated with increased sensitivity to chemotherapeutic agents, including docetaxel, doxorubicin, gemcitabine, paclitaxel, tamoxifen, and vinorelbine. Knockdown of EHHADH reduced BLBC cell proliferation and migration. Virtual screening revealed several candidate small molecules targeting EHHADH.
conclusionThis study establishes a prognostic model based on beta-alanine metabolism in BLBC and identifies EHHADH as a potential biomarker and drug target, providing insights for precision therapy in metabolically reprogrammed breast cancer.
Indexed as
Identifiers
41042469What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.